Alaunos Therapeutics, Inc. (TCRT)

Alaunos Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	6.06	53.04	76.1	115.2	79.87
Cash & Cash Equivalents	6.06	53.04	76.1	115.2	79.87
Cash Growth	-88.57%	-30.30%	-33.94%	44.23%	29.12%
Receivables	0	0	1.11	4.67	3.33
Other Current Assets	2.2	0.76	1.62	10.73	22.29
Total Current Assets	8.26	53.8	78.83	130.59	105.49
Property, Plant & Equipment	0	10.6	15.36	14.88	3.38
Other Long-Term Assets	0	0.54	0.67	0.88	0.24
Total Long-Term Assets	0	11.14	16.03	15.76	3.62
Total Assets	8.26	64.94	94.87	146.35	109.11
Accounts Payable	0.62	1.39	1.37	0.96	0.91
Current Debt	0	17.32	8.6	0	0
Other Current Liabilities	1.34	5.45	6.08	17.41	11.62
Total Current Liabilities	1.96	24.17	16.04	18.37	12.53
Long-Term Debt	0	2.19	20.77	4	1.58
Other Long-Term Liabilities	0	0.03	0	0	0
Total Long-Term Liabilities	0	2.22	20.77	4	1.58
Total Liabilities	1.96	26.38	36.81	22.36	14.1
Total Debt	0	19.51	29.37	4	1.58
Debt Growth	-	-33.56%	635.04%	153.17%	-
Retained Earnings	-915.77	-880.63	-842.85	-764.1	-684.13
Shareholders' Equity	6.31	38.56	58.06	123.98	95.01
Net Cash / Debt	6.06	33.53	46.73	111.2	78.29
Net Cash / Debt Growth	-81.92%	-28.26%	-57.98%	42.04%	26.57%
Net Cash Per Share	0.38	2.32	3.27	7.96	6.99
Working Capital	6.31	29.63	62.79	112.22	92.97
Book Value Per Share	0.39	2.66	4.06	8.87	8.48

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).